SCOTT ZELA: Open Payments
NPI 1326044306 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$14,500 in 99 payments from 12 companies in 2025. Trend: 2023 $1,382 · 2024 $7,479 · 2025 $14,500
Speaker / faculty: $8,640Travel & lodging: $3,737Food & beverage: $1,718Consulting: $405
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 30 | $13,045 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 23 | $361 |
| Gilead Sciences, Inc. | 12 | $343 |
| Ipsen Biopharmaceuticals, Inc | 15 | $335 |
| ABBVIE INC. | 8 | $174 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $96 |
| ORPHALAN INC | 2 | $36 |
| Mallinckrodt Hospital Products Inc. | 1 | $33 |
| Mirum Pharmaceuticals, Inc. | 1 | $22 |
| VIVUS LLC | 1 | $21 |
Products named: REZDIFFRA, XIFAXAN, IQIRVO, LIVTENCITY, MAVYRET, CREON, CUVRIOR, TERLIVAZ.
Industry payments across TX — which companies pay providers there.
